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Kline Beechamによる Diversified Pharmaceuticals Services買収（同23億ドル，1994年
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 Institutional Setting and Innovation
 
Seiichiro YONEKURA and Osamu SUZUKI
《Abstract》
It is entrepreneurs who carry out innovations.Therefore, the most
 
important factor to facilitate innovation is entrepreneurial activity.
The more capable are entrepreneurs,however,the more serious consid-
eration they pay to the environment where they would carry out innova-
tion.In this sense,institutional setting is still of vital importance to the
 
entrepreneurial activity.Particularly in the knowledge intensive indus-
tries such as electronics,computer,software,bio-medical technologies
 
and so on, legal condition, knowledge infrastructure, university-
business relation,national policies on science,business and comeptitive-
ness and other institutional settings are critical to innovative decision.
This paper will examine institutional settings for new pharmaceutical
 
exploration and development in Japan in comparison with those of the
 
United States,or other European countries.Major focus is on institu-
tional differences in terms of a) preparations for market launch
 
approval application, b) official examination of applications and c)
reimbursement prices for pharmaceuticals.It is argued that the unique
 
institution of Japanese pharmaceutical industry,such as governmental-
ly controlled reimbursement prices or doctors extraordinary bargaining
 
power,is found to charge extra transaction(and transformation)costs
 
on earning market launch approvals,as well as on investing substantial
 
resources in research and development activities in Japan. Several
 
evidences that show both comparative deficiencies and recent sharp
 
decreases in new pharmaceutical approvals in Japan are cited as
 
economic consequences resulted from additional transaction(and trans-
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formation)costs suffered by Japanese pharmaceutical firms. Signifi-
cant lack of incentives for new pharmaceutical development is also
 
attributed to institutionally burdened transaction (and transformation)
costs. Some implications, including urgent need for restructuring the
 
Japanese institutions or unique importance of universities and biotech
 
ventures spun out from universities,are discussed based on the results
 
of the analysis.
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